RT Journal Article
SR Electronic
T1 Innate immune genes distinguish the immune microenvironment of early onset colorectal cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.26.20141143
DO 10.1101/2020.06.26.20141143
A1 Gardner, Ivy H.
A1 Siddharthan, Ragavan
A1 Watson, Katherine
A1 Dewey, Elizabeth
A1 Ruhl, Rebecca
A1 Guan, Xiangnan
A1 Xia, Zheng
A1 Tsikitis, Liana V.
A1 Anand, Sudarshan
YR 2020
UL http://medrxiv.org/content/early/2020/06/28/2020.06.26.20141143.abstract
AB Despite a decrease in the incidence of colorectal cancer (CRC) over the last 40 years, the incidence of CRC in people under 50 years old is increasing around the globe. Early onset (≤50 years old) and late onset (≥65 years old) CRC appear to have differences in their clinicopathological and genetic features, but it is unclear if there are differences in the tumor microenvironment. We hypothesized that the immune microenvironment of early onset CRC is distinct from late onset CRC and promotes tumor progression. We used Nanostring immune profiling to analyze mRNA expression of immune genes in FFPE surgical specimens from patients with early (N=40) and late onset (N=39) CRC. We found three genes, SAA1, C7, and CFD, have increased expression in early onset colorectal cancer and distinct immune signatures based on the tumor location. After adjusting for clinicopathological features, increased expression of CFD and SAA1 were associated with worse progression free survival and increased expression of C7 was associated with worse overall survival. Our data demonstrate that the immune microenvironment in early onset CRC is unique, location dependent, and associated with worse outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from NIH to S.A. (R01 HL137779 and R01 HL143803).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the OHSU Institutional Review Board (study #00021278). Only patients who had undergone informed consent to be included in the Oregon Colorectal Cancer Registry were included in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData that is not included in the supplementary material is available upon request from the corresponding author.